Keyphrases
Cyclophosphamide
100%
Metastatic Melanoma
100%
Dimethyl
100%
Carboxamide
100%
Imidazole
100%
Adjuvant Chemotherapy
100%
Chemotherapy
66%
Melanoma
66%
Therapeutic Effect
66%
Metastatic Stage
66%
Disease Stage
33%
Overall Survival
33%
Metastasis
33%
Metastasis Sites
33%
Distant Metastasis
33%
Nausea
33%
Parvum
33%
Vomiting
33%
Disease-free Survival
33%
Clinical High Risk
33%
High-risk Population
33%
Subcutaneous Injection
33%
Corynebacterium Parvum
33%
Randomized Prospective Trial
33%
Complete Surgical Resection
33%
Regional Metastasis
33%
Chemoimmunotherapy
33%
Hair Loss
33%
Adjuvant Immunotherapy
33%
Medicine and Dentistry
Dacarbazine
100%
Metastatic Melanoma
100%
Cyclophosphamide
100%
Adjuvant Chemotherapy
100%
Disease
66%
Nodular Melanoma
66%
Metastatic Carcinoma
66%
Therapy Effect
66%
High Risk Population
33%
Surgery
33%
Immunotherapy
33%
Distant Metastasis
33%
Disease Free Survival
33%
Propionibacterium acnes
33%
Overall Survival
33%
Nausea and Vomiting
33%
Chemoimmunotherapy
33%
Subcutaneous Injection
33%
Regional Metastasis
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Dacarbazine
100%
Metastatic Melanoma
100%
Cyclophosphamide
100%
Disease
50%
Melanoma
50%
Therapeutic Effect
50%
Immunotherapy
25%
Overall Survival
25%
Disease Free Survival
25%
Distant Metastasis
25%
Nausea and Vomiting
25%
Subcutaneous Injection
25%
Regional Metastasis
25%
Propionibacterium acnes
25%
Hair Loss
25%
Immunology and Microbiology
Cyclophosphamide
100%
High Risk Population
33%
Immunotherapy
33%
Overall Survival
33%
Disease Free Survival
33%
Propionibacterium acnes
33%